I asked an LLM a question that junior biostatisticians ask senior biostatisticians all the time: Should I use a Bayesian borrowing design for my Phase 2 single-arm oncology trial? Here's what I got back. The LLM Response Should I use a Bayesian borrowing design for my Phase 2
The pharmaceutical industry is facing a cost disease. Bringing a new drug to market now routinely exceeds $2 billion, with patient recruitment standing as the single largest bottleneck. In response, we usually reach for operational fixes: faster sites, simpler protocols, digital recruitment. But there is a mathematical lever that is
What to do instead of UPSIs
